Helping to share the web since 1996


C

CAR-T

@bellasmith
United States United States


CAR-T
45-1 Ramsey Road, Shirley, NY 11967, USA
Shirley
NY
11967
United States

Bella bellasmith
@bellasmith
Flag of United States
5166698109

Websites & Listings

Conjugate Vaccine

Vaccines can be prophylactic (e.g. to prevent or reduce the impact of a future infection by a pathogen), or therapeutic (e.g. cancer vaccines are being investigated). Vaccines exist in many different forms which may contain live, attenuated virus.

View Review Page →

ipatasertib

Ipatasertib, also known as GDC-0068, is a strong ATP-competitive pan-AKT inhibitor. It was initially derived during the screening and optimization process of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds.

View Review Page →

Epothilones

Epothilones, commonly referred to as macrolide compounds, were initially discovered in 1987 from the fermentation products of soil bacteria. They are a group of anti-cancer drugs with high potency.

View Review Page →

Duocarmycin ADC

Duocarmycins are a series of natural products originally isolated from Streptomyces bacteria in 1988. They exhibit an impressively high cytotoxicity and are subsequently developed into anti-tumor agents.

View Review Page →

ADC payload

Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents that are constructed by the covalent coupling of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. As a key factor in an ADC, the payload d

View Review Page →

Cysteine conjugation

As an industrial leader in antibody-drug conjugate (ADC) development and with our experienced science teams, Creative Biolabs provides the most comprehensive cysteine-based conjugation approaches to generate highly customized ADCs in a timely.

View Review Page →

ADC linkers?

Creative Biolabs offers a variety of chemically versatile linker molecules to facilitate antibody-drug conjugate (ADC) development projects. All chemical linkers are of >95% purity and they are the basic building blocks for a successful ADC.

View Review Page →

Auristatin

Auristatins are a family of complex analogues to the native antineoplastic product dolastatin 10. They are 100 to 1000 times more toxic than Doxorubicin, a conventional cancer chemotherapy medication.

View Review Page →

ADC antibody

As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse

View Review Page →

Doxorubicin moa

Doxorubicin, often regarded by the trade name “adriamycin”, is a member of the anthracycline compounds derived from Streptomyces peucetius var. caesius in the 1960s.

View Review Page →

Akt inhibitor

Ipatasertib, also known as GDC-0068, is a strong ATP-competitive pan-AKT inhibitor. It was initially derived during the screening and optimization process of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds.

View Review Page →

Dhfr methotrexate

Methotrexate, a folate analogue, was initially synthesized in the 1940s to serve as a dihydrofolate reductase (DHFR) inhibitor.

View Review Page →

Linker peptide

Peptide linkers belong to protease-sensitivity linkers (also called enzymatically cleavable linkers) that have gained significant attention in ADC development due to their superior plasma stability and controled payload release mechanism.

View Review Page →

CD19

Currently, anti-CD19 CAR-T cell therapies for B-cell malignancies are the most advanced engineered T cell therapies being tested. Clinical trials in ALL and CLL have exhibited robust and striking clinical efficacy.

View Review Page →

Car t biomarker

In a narrow sense of cancer biomarker, it is limited to proteins the most used to challenge in the clinical applications, especially in the CAR-T therapy.

View Review Page →

Car t cell evaluation

At Creative Biolabs, our scientists will professionally perform multiple evaluations on the post-transfection CAR-T cells to verify the solid success of CAR-T construction and superior function. With advanced technologies and experienced researchers.

View Review Page →

Car design development

In detail, CAR stands for chimeric antigen receptor or artificial T cell receptor, which is engineered elaborately and endowing an immune effector cell (T cell) with an arbitrary specificity via a monoclonal antibody.

View Review Page →

Chimeric Antigen Receptor

Our novel Chimeric Antigen Receptor (CAR) technology platform consists of several key services including CAR construction, pseudoviral particles production and stable transduction.

View Review Page →

in vivo animal testing

Taking advantage of the CellRapeutics™ platform, Creative Biolabs provides customized, standardized, reliable and high-quality CAR-T preclinical in vivo assay services for clients across the world.

View Review Page →

Creative Biolabs

As a leading technology provider, Creative Biolabs has established a solid platform for offering a variety of CAR products. Our brilliant scientists can design tailor-made solutions to fit your exact needs.

View Review Page →

Car t therapy

The typical structure of a CAR molecule includes a single chain variable fragment (scFv), a spacer, a transmembrane domain (TM) and an intracellular signaling domain.

View Review Page →

lentiviral vector

Aiming at genetically modifying T cells with designed CAR, our scientists flexibly adopt versatile methodologies to transfect CAR construction into T cells, such as packing and transfection with virus based transfection methods.

View Review Page →

ADC characterization

Pharmacokinetics (PK) studies provide critical information regarding the behavior of a drug in circulation and its ultimate form after extensive in vivo metabolism.

View Review Page →

Adc linker

Creative Biolabs offers a variety of chemically versatile linker molecules to facilitate antibody-drug conjugate (ADC) development projects. All chemical linkers are of >95% purity and they are the basic building blocks for a successful ADC.

View Review Page →

Cysteine conjugation

Cysteine residues serve essential roles in protein structure and function due to their highly reactive thiol side chains that form inter or intra molecular di-sulfide bonds to enable correct protein folding.

View Review Page →

Duocarmycin

Duocarmycins are a series of natural products originally isolated from Streptomyces bacteria in 1988. They exhibit an impressively high cytotoxicity and are subsequently developed into anti-tumor agents.

View Review Page →

Antibody drug conjugate linker

Linker design for ADCs is highly dependent on the biolology of the target cells, the characteristics of the antibody, and the structure of the drug molecule.

View Review Page →

Dhfr methotrexate

Methotrexate, a folate analogue, was initially synthesized in the 1940s to serve as a dihydrofolate reductase (DHFR) inhibitor. It has a core structure comprised of an amino group (NH2) associated with a totally oxidized pteridine ring.

View Review Page →

CAR T gene structure

Different from the structure of classical CAR molecule, our scientists utilize biotin or anti- Fluorescein isothiocyanate (FITC) single-chain variable fragment (scFv) as targeting region fused.

View Review Page →

Biomarker identification

In a narrow sense of cancer biomarker, it is limited to proteins the most used to challenge in the clinical applications, especially in the CAR-T therapy.

View Review Page →

CAR T cell proliferation assay

Our scientists have developed the second and the third generation CAR products, which can enhance the persistence of CAR-T cells or -NK cells proliferation.

View Review Page →

amyloid precursor protein antibody

Creative Biolabs is the leading manufacturer that has extensive experience in various antibody production and engineering fields.

View Review Page →

Amyloid precursor protein antibody

Creative Biolabs is the leading manufacturer that has extensive experience in various antibody production and engineering fields.

View Review Page →

Smcc

Linkers facilities the conjugation of ADC toxins to antibodies and in the meantime, they also dictate the release mechanism of an ADC. Proper linker selection will not only ease the process of obtaining the conjugate but also help enhance the chemica

View Review Page →

Cysteine maleimide

Cysteine residues serve essential roles in protein structure and function due to their highly reactive thiol side chains that form inter or intra molecular di-sulfide bonds to enable correct protein folding. Thiol reactivity also provides an appealin

View Review Page →

Adc payload

Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents that are constructed by the covalent coupling of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. As a key factor in an ADC, the payload d

View Review Page →

Duocarmycin adc

Duocarmycins are a series of natural products originally isolated from Streptomyces bacteria in 1988. They exhibit an impressively high cytotoxicity and are subsequently developed into anti-tumor agents. Duocarmycin analogues, among which CC-1065.

View Review Page →

Chimeric Antigen Receptor

The basic CAR structure consists of an extracellular antigen-recognition domain attached to an extracellular spacer domain, a trans-membrane region that anchors the receptor in the plasma, and a signaling endodomain.

View Review Page →

Cleavable linker

Linker design for ADCs is highly dependent on the biolology of the target cells, the characteristics of the antibody, and the structure of the drug molecule. Selection of the optimal linker is achieved through efficacy and toxicity assessments for ea

View Review Page →

Chimeric Antigen Receptor

Our novel Chimeric Antigen Receptor (CAR) technology platform consists of several key services including CAR construction, pseudoviral particles production and stable transduction, meanwhile we also offer a series of high quality functional analysis.

View Review Page →

TCR technology

With high-affinity TCR technology, Creative Biolabs is capable of identifying the candidate target tumor antigen and the sequence of tumor-specific TCR to create tumor-specific T cells.

View Review Page →

Creative Biolabs

As a leading technology provider, Creative Biolabs has established CellRapeutics™ Chimeric Antigen Receptor (CAR) Technology platform. Our elite scientists have broad experience in CAR construction, which can supply the best service for you.

View Review Page →

CAR T solution

Creative Biolabs is a world-renowned service provider for immunotherapy. We have one of the world’s largest collection of CAR products of different generations targeting various biomarkers.

View Review Page →

Next generation CAR T

To augment the antitumor efficacy of 1st-generation CARs, the 2nd-generation CARs were designed to combine the intracellular signaling domains from various costimulatory protein receptors.

View Review Page →

lentiviral car

Lentiviral (complex retrovirus) transfection is also one of the mainstays of current gene therapy approaches, which enable the integration of artificial genes into the host genome in a stable status for genetical modifications in actively dividing ce

View Review Page →

CAR T genes

Although the T cells are difficult to modify using non-viral methods like lipid-based car t plasmid transfection due to the high toxicity and low efficiency, the electroporation and several virus-based transfection systems are much more robust.

View Review Page →

CAR T scfv

Without a doubt, a superior scFv leads to an even more superior CAR-T therapy. Creative Biolabs manifests as a world leading expert in antibody engineering field and provides our clients with the best scFv .

View Review Page →

Vaccine biopharma

As a professional pre-clinical vaccine development and production company, Creative Biolabs has effectively supported the vaccine industry for decades with a full range of vaccine design and production services and related products.

View Review Page →

CAR T for autoimmune disease

There are as many as 80 types of autoimmune diseases. Many of them have similar symptoms, which makes them very difficult to diagnose.

View Review Page →

GLP vaccine development

Pre-clinical guidelines for vaccines have been produced since 1997. Pre-clinical in vivo assessments are crucial to the assessment of potency and safety of human vaccines. Efficient translation from basic research to clinical therapies will depend.

View Review Page →




Publishers can upgrade to remove these ads